Postnatal manipulation of β adrenergic receptor activity via daily oral treatment with ADRβ2 agonist and ADRβ1/β3 antagonists improved whole‐body glucose utilization rates and basal insulin sensitivity in IUGR lambs. This evidence concerns the gene ADRB1 and fetal growth restriction.